Kestra Medical Technologies, Ltd. is a commercial-stage medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular care. Founded in 2014 and headquartered in Kirkland, Washington, the company develops intuitive, intelligent, and connected monitoring and therapeutic intervention technologies. Kestra's flagship product is the ASSURE Wearable Cardioverter Defibrillator (WCD) system, which is designed to protect patients at risk of sudden cardiac arrest. The system integrates advanced sensors, real-time data analytics, and a wearable garment to continuously monitor a patient's heart rhythm and automatically deliver a life-saving defibrillation shock if a dangerous arrhythmia is detected.
The company's business model combines the provision of its proprietary hardware with a digital health platform that enables remote patient monitoring, allowing healthcare providers to track patient data and recovery progress. Revenue is primarily generated through the prescription, deployment, and reimbursement of its wearable devices and associated digital services. Operating primarily in the United States, Kestra competes in the specialized cardiovascular medical device market against established players by emphasizing patient comfort, compliance, and integrated digital connectivity to improve the patient experience. The company went public on the Nasdaq in March 2025, raising capital to expand its commercial footprint, scale its manufacturing capabilities, and further develop its pipeline of cardiac monitoring and therapeutic solutions.
